CD163 and primary biliary cholangitis: Currently, there is a clinical focus on identifying noninvasive markers of disease progression, prognosis, and treatment response in PBC research.45,46 This is the first study to present repeated measurements of the macrophage activation marker sCD163 before and after UDCA treatment, and to show that the marker decreases after UDCA treatment.